Read + Share
Zhang J, Shi Y, Zhang Q, Du Y, et al. Activity and safety of first-line pumitamig plus nab-paclitaxel in
triple-negative breast cancer: a single-arm, phase 1b/2 trial. Lancet Oncol 2026 Nov 5:S1470-2045(26)00378.
PMID: 42987884
|
 |
|
Zhang J, Shi Y, Zhang Q, Du Y, et al. Activity and safety of first-line pumitamig plus nab-paclitaxel in
triple-negative breast cancer: a single-arm, phase 1b/2 trial. Lancet Oncol 2026 Nov 5:S1470-2045(26)00378.
PMID: 42987884
|
|
|
|